Abstract
P-58 An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have